Building High-Performance Cell Factories through Systematic Pathway Balancing. Escherichia coli is the most widely utilized host for metabolic engineering and biomanufacturing. However, achieving industrial-scale titers for biofuels, pharmaceuticals, or bulk chemicals requires more than simple gene expression; it demands a systematic approach to balance complex metabolic networks. CD Biosynsis integrates Modular Engineering strategies, Constraint-based Metabolic Modeling, and Computational Optimization Algorithms to provide comprehensive E. coli pathway optimization. Our services are designed to eliminate metabolic bottlenecks and maximize carbon flux toward your target product while maintaining host robustness.
Get a Technical QuoteOur platform addresses metabolic optimization at multiple levels—from fine-tuning individual enzyme translation to reconstructing genome-wide metabolic networks for commercial viability.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Gene-Level Tuning | RBS/Promoter Library Screening | Fine-tuning individual gene expression levels | Expression profiles + Validated strains |
| Modular Optimization | Pathway Recasting & Inter-module Balancing | Coordinating multi-gene pathways for complex metabolites | Engineered strains + Module flux data |
| Pathway Balancing | Combinatorial Transcription & Translation Tuning | Removing bottlenecks in multi-step pathways | Optimized strains + Titer/Yield analysis |
| Genome-Scale Design | MOME Optimization Algorithm | In silico prediction of knockouts & up-regulations | Genetic design map + Pareto optimal strains |
1. Pathway Design & Modeling
2. Module Construction
3. Combinatorial Optimization
4. Scale-up Assessment
Identification of the target pathway and in silico simulation using genome-scale metabolic networks.
Formal project proposal and Mutual NDA signing.
Dividing the pathway into logical modules and constructing synthetic operons for combinatorial testing.
Application of modular engineering strategies to build functional units.
Balancing modules through transcriptional tuning and RBS customization to harmonize cofactor and precursor supply.
High-throughput screening followed by batch or fed-batch fermentation.
Evaluation of genetic stability and metabolic performance under simulated industrial fermentation conditions.
Final delivery of optimized strains and comprehensive productivity reports.
To provide the highest level of service, our team continuously benchmarks our internal protocols against landmark studies in the field of E. coli engineering.
Academic research has demonstrated that recasting E. coli metabolism into three discrete modules—upstream acetyl-CoA formation, intermediary activation, and downstream synthase modules—can systematically remove bottlenecks. This approach, combined with customized RBS for translation refinement, has led to significant improvements in fatty acid production, achieving titers as high as 8.6 g/L.
(Reference: Xu et al., Nature Communications)
In silico multi-objective optimization algorithms, such as MOME, are powerful for identifying the optimal balance between cell growth and product synthesis. By analyzing multiple genome-scale metabolic networks, researchers have identified specific knockout sets that increase ethanol production by over 800% compared to wild-type strains.
(Reference: Patane et al., Annals of Operations Research)
The successful commercialization of bio-chemicals requires the deep integration of metabolic engineering with fermentation technology. Benchmarking against successful industrial cases (e.g., 1,3-propanediol or aromatic production) allows us to focus on enhancing carbon efficiency and product purity, effectively shrinking development cycles for new bioproducts.
(Reference: Chotani et al., Biochimica et Biophysica Acta)
1. How do you identify which part of a pathway is the bottleneck?
We use a combination of flux balance analysis (FBA) and modular testing. By varying the expression levels of different modules, we can pinpoint which step limits the overall production rate.
2. What is the benefit of the MOME algorithm?
MOME allows us to look at the entire cell's metabolism rather than just the target pathway. It predicts non-obvious gene knockouts that improve production while maintaining biomass.
3. Do you provide strains suitable for large-scale fermentation?
Yes. Our process includes assessing genetic stability and metabolic performance under conditions that mimic industrial-scale fermentation environments.
4. How do you handle imbalances in cofactors like NADH or NADPH?
We optimize redox balance by fine-tuning the expression of modules that produce or consume these cofactors, ensuring continuous metabolic flux.
5. What is the typical timeline for an optimization project?
Depending on the complexity of the metabolic network, a project typically takes 3 to 6 months from initial design to delivery.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.